Clinical Trial: NCT02644369
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | University Health Network, Toronto |
| Information Provided By: | University Health Network, Toronto |
| Last Update Posted: | 2026-10-01 |
Study Overview
Brief Summary
This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment.
Pembrolizumab is a monoclonal antibody that is designed to block a protein called programmed cell death 1 ligand 1 (PD-L1) which will allow the body's immune system to kill the cancer cells.
Official Title
Conditions
Intervention / Treatment
- Biological: Pembrolizumab
Other Study ID Numbers
- INSPIRE-001
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | University Health Network, Toronto |
| Information Provided By: | University Health Network, Toronto |
| Last Update Posted: | 2026-10-01 |
Study Overview
Brief Summary
This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment.
Pembrolizumab is a monoclonal antibody that is designed to block a protein called programmed cell death 1 ligand 1 (PD-L1) which will allow the body's immune system to kill the cancer cells.
Official Title
Conditions
Intervention / Treatment
- Biological: Pembrolizumab
Other Study ID Numbers
- INSPIRE-001